Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab, Surufatinib and HAIC in Advanced Intrahepatic Cholangiocarcinoma
NCT06375642Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2024
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, surufatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2024; status: not yet recruiting.
02
Drugs
adebrelimabsurufatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06375642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375642.